Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer

  • Anil Kapoor McMaster University
  • Emily C.L. Wong McMaster University
  • Wayne Fang McMaster University
  • Nathan C. Wong McMaster University
Keywords: cytoreductive nephrectomy, metastatic kidney cancer, mRCC

References

Flanigan RC, Mickisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004 Mar;171(3):1071-6. Available from: doi: 10.1097/01.ju.0000110610.61545.ae [Accessed 2018 Aug 8].

Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001 Dec;345(23):1655-9. Available from: 10.1056/NEJMoa003013 [Accessed 2018 Aug 8].

Mickisch GH, Garin A, Van Poppel H, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001 Sep;358(9286):966-70.4. Available from: doi: 10.1016/S0140-6736(01)06103-7 [Accessed 2018 Aug 8].

Heng DY, Rini BI, Beuselinck B, et al. Cytoreductive nephrectomy (CN) in patients with synchronous metastases from renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC). Eur Urol 2014 Oct; ;66(4):704-10. Available from: doi: 10.1016/j.eururo.2014.05.034 [Accessed 2018 Aug 10].

Powles T, Kayani I, Blank C, et al. The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer. Ann Oncol 2011 Jan;22(5):1041-7. Available from: doi: 10.1093/annonc/mdq564 [Accessed 2018 Aug 10].

Powles T, Sarwar N, Stockdale A, et al. Safety and efficacy of pazopanib therapy prior to planned nephrectomy in metastatic clear cell renal cancer. JAMA Oncol 2016 Oct;2(10):1303-9. Available from: doi: 10.1001/jamaoncol.2016.1197 [Accessed 2018 Aug 10].

Motzer RJ, Russo P. Cytoreductive Nephrectomy—Patient Selection Is Key. N Engl J Med 2018 Aug 2;379(5):481-2. Available from: doi: 10.1056/NEJMe1806331 [Accessed 2018 Aug 10].

Stewart GD, Aitchison M, Bex A, et al. Cytoreductive nephrectomy in the tyrosine kinase inhibitor era: a question that may never be answered. Eur Urol 2017 Jun;71(6):845-7. Available from: doi: 10.1016/j.eururo.2016.10.029 [Accessed 2018 Aug 10].

Méjean A, Ravaud A, Thezenas S, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl J Med 2018 Aug;379(5):417-427. Available from: doi: 10.1056/NEJMoa1803675 [Accessed 2018 Aug 10].

Bex, A, Mulders, P, Jewett, M, et al. Immediate versus deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. in ESMO Congress Madrid 2017 (2017) [Accessed 2018 Aug 10].

Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014 Sep;25(suppl 3):iii49-56. Available from: doi: 10.1093/annonc/mdx258 [Accessed 2018 Aug 10].

Bex A, Mulders P, Jewett MA, et al. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Ann Oncol 2017 Sep;28(suppl 5) [Accessed 2018 Aug 10].

Silberstein JL, Adamy A, Maschino AC, et al. Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC). BJU Int 2012 Nov;110(9):1276-82. Available from: doi: 10.1111/j.1464-410X.2012.11103.x [Accessed 2018 Aug 10].

Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med 2018 Apr;378(14):1277-90. Available from: doi: 10.1056/NEJMoa1712126 [Accessed 2018 Aug 10].

Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial. J Clin Oncol 2017 Feb;35(6):591-7. Available from: doi: 10.1200/JCO.2016.70.7398 [Accessed 2018 Aug 10].

Published
2019-02-26
How to Cite
Kapoor, A., Wong, E. C., Fang, W., & Wong, N. C. (2019). Upfront cytoreductive nephrectomy vs. upfront systemic therapy in metastatic kidney cancer. Canadian Urological Association Journal, 13(11), E377-81. https://doi.org/10.5489/cuaj.5666
Section
Research Letter